Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 05, 2015 7:30 AM ET

Biotechnology

Company Overview of Advaxis, Inc.

Company Overview

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also develop...

305 College Road East

Princeton, NJ 08540

United States

Founded in 2002

20 Employees

Phone:

609-452-9813

Fax:

609-452-9818

Key Executives for Advaxis, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Age: 46
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Age: 55
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

Advaxis, Inc. Key Developments

Advaxis, Inc. Appoints Shelonitda S. Rose as Vice President, Clinical Development

Advaxis, Inc. announced that it has appointed Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research. In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis's Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company's Lm Technology™ platform. Most recently, Dr. Rose served as Director, Oncology Clinical Research for Merck & Co., Inc.

Advaxis, Inc.(NasdaqCM:ADXS) added to Russell 2000 Index

Advaxis, Inc. will be added to Russell 2000 Index

Advaxis, Inc.(NasdaqCM:ADXS) added to Russell 3000 Index

Advaxis, Inc. will be added to the Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
Rousselot Peabody Inc United States
Spectra Stable Isotopes United States
Inception IBD, Inc. United States
Forelight, Inc. United States
Inhibrx LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advaxis, Inc., please visit www.advaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.